+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 45Years +
All Genders
ID07220876

Evaluating the Safety and Effectiveness of the VisiPlate Glaucoma Implant in Adults with Refractory Open-Angle Glaucoma A Prospective Multicenter Study

Led by Avisi Technologies Inc. · Updated on 2026-10-07

165

Participants Needed

14

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of the VisiPlate Aqueous Shunt, a tiny implant designed to lower eye pressure in patients with refractory open-angle glaucoma. This condition includes open angle, pseudoexfoliative, or pigmentary glaucoma where other medical and surgical treatments have not succeeded. The trial is prospective, multicenter, single-arm, and open-label, focusing on treatment for adults aged 45 and older. Participants will receive the VisiPlate Glaucoma Implant, a device placed in the eye to help reduce intraocular pressure between 20 and 40 mmHg. The study will follow participants for at least 12 months to observe changes in eye pressure and the proportion of subjects achieving a 20% or greater reduction in mean diurnal intraocular pressure. Throughout the study, participants will undergo regular evaluations of their eye pressure and visual function, including measuring visual field changes and assessing the implanted device. The main outcome is the reduction in eye pressure at 12 months, with safety monitored by observing any eye infections, inflammation, or other complications. The total duration of participation aligns with the 12-month follow-up period to assess the implants effectiveness and safety.

CONDITIONS

Brief Title

Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

Research Team

K

Katherine Lee

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here